Related Experiment Video

Updated: Jul 20, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Occurrence of CNS demyelinating disease in patients with myasthenia gravis

Marc Gotkine1, Yakov Fellig, Oded Abramsky

  • 1Department of Neurology, Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, Jerusalem, Israel. marclana@012.net.il

Neurology
|September 13, 2006
PubMed

Insights

Patients with myasthenia gravis (MG) show an increased risk of central nervous system demyelinating disease (CNSDD). This neurological condition, often myelitis, occurred in 2.3% of MG patients and may be linked to treatments like thymectomy.

Area of Science:

  • Neuroimmunology
  • Neurology

Background:

  • An increased incidence of multiple sclerosis (MS) has been observed in patients diagnosed with myasthenia gravis (MG).
  • Central nervous system demyelinating disease (CNSDD) represents a spectrum of neurological disorders.
  • The relationship between MG and secondary CNSDD requires further investigation.

Purpose of the Study:

  • To determine the incidence of CNS demyelinating disease (CNSDD) in patients with myasthenia gravis (MG).
  • To identify clinical characteristics and potential risk factors associated with CNSDD in MG patients.

Main Methods:

  • Retrospective review of medical records for 214 patients diagnosed with myasthenia gravis (MG).
  • Analysis of patient histories to identify occurrences of central nervous system demyelinating disease (CNSDD).
  • Evaluation of clinical manifestations, diagnostic markers (e.g., antinuclear antibodies), and treatment history.

Main Results:

  • Central nervous system demyelinating disease (CNSDD) was diagnosed in five patients (2.3%) with myasthenia gravis (MG).
  • CNSDD diagnoses consistently occurred after the initial MG diagnosis.
  • Myelitis, including recurrent forms, was the most frequent central nervous system manifestation observed.
  • All affected patients tested positive for antinuclear antibodies.

Conclusions:

  • Central nervous system demyelinating disease (CNSDD) appears to occur more frequently in patients with myasthenia gravis (MG) than previously recognized.
  • The development of CNSDD in MG patients may be associated with immune-modulating therapies, such as thymectomy.
  • Further research is warranted to elucidate the underlying mechanisms and optimize management strategies for comorbid MG and CNSDD.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...